RU2019120680A3 - - Google Patents

Download PDF

Info

Publication number
RU2019120680A3
RU2019120680A3 RU2019120680A RU2019120680A RU2019120680A3 RU 2019120680 A3 RU2019120680 A3 RU 2019120680A3 RU 2019120680 A RU2019120680 A RU 2019120680A RU 2019120680 A RU2019120680 A RU 2019120680A RU 2019120680 A3 RU2019120680 A3 RU 2019120680A3
Authority
RU
Russia
Application number
RU2019120680A
Other versions
RU2750539C2 (ru
RU2019120680A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019120680A3 publication Critical patent/RU2019120680A3/ru
Publication of RU2019120680A publication Critical patent/RU2019120680A/ru
Application granted granted Critical
Publication of RU2750539C2 publication Critical patent/RU2750539C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2019120680A 2017-02-08 2018-02-06 Фармацевтическая композиция для лечения опухоли RU2750539C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017021542 2017-02-08
JP2017-021542 2017-02-08
PCT/JP2018/004007 WO2018147275A1 (ja) 2017-02-08 2018-02-06 腫瘍治療用医薬組成物

Publications (3)

Publication Number Publication Date
RU2019120680A3 true RU2019120680A3 (ru) 2021-03-09
RU2019120680A RU2019120680A (ru) 2021-03-09
RU2750539C2 RU2750539C2 (ru) 2021-06-29

Family

ID=63107502

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019120680A RU2750539C2 (ru) 2017-02-08 2018-02-06 Фармацевтическая композиция для лечения опухоли

Country Status (13)

Country Link
US (1) US20190388420A1 (ru)
EP (1) EP3581183B1 (ru)
JP (1) JP6581320B2 (ru)
KR (1) KR102539920B1 (ru)
CN (1) CN110072528B (ru)
AU (1) AU2018219637B2 (ru)
BR (1) BR112019014127A2 (ru)
CA (1) CA3044658A1 (ru)
ES (1) ES2971448T3 (ru)
IL (1) IL267159B (ru)
MX (1) MX2019006504A (ru)
RU (1) RU2750539C2 (ru)
WO (1) WO2018147275A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
RU2729936C2 (ru) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противораковое средство
EP4051278A1 (en) * 2019-10-29 2022-09-07 Eisai R&D Management Co., Ltd. Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
CN117794544A (zh) * 2021-09-08 2024-03-29 卫材R&D管理有限公司 实体瘤治疗用医药组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
ES2318649T3 (es) 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 c−Kitキナーゼ阻害剤
JP2005008534A (ja) 2003-06-17 2005-01-13 Soc De Conseils De Recherches & D'applications Scientifiques (Scras) 抗癌剤及び癌の治療方法
EP1925941B1 (en) 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
CA2723617A1 (en) 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2014208774A1 (en) * 2013-06-26 2014-12-31 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
US9174998B2 (en) * 2013-12-25 2015-11-03 Eisai R&D Management Co., Ltd. (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
RU2729936C2 (ru) * 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противораковое средство
WO2016208576A1 (ja) * 2015-06-23 2016-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 (6S,9aS)-N-ベンジル-6-[(4-ヒドロキシフェニル)メチル]-4,7-ジオキソ-8-({6-[3-(ピペラジン-1-イル)アゼチジン-1-イル]ピリジン-2-イル}メチル)-2-(プロプ-2-エン-1-イル)-オクタヒドロ-1H-ピラジノ[2,1-c][1,2,4]トリアジン-1-カルボキサミド化合物の結晶

Also Published As

Publication number Publication date
MX2019006504A (es) 2019-08-14
BR112019014127A2 (pt) 2020-02-11
JPWO2018147275A1 (ja) 2019-11-07
ES2971448T3 (es) 2024-06-05
AU2018219637B2 (en) 2023-07-13
AU2018219637A1 (en) 2019-05-23
KR20190110525A (ko) 2019-09-30
EP3581183A1 (en) 2019-12-18
WO2018147275A1 (ja) 2018-08-16
US20190388420A1 (en) 2019-12-26
IL267159A (en) 2019-10-31
CA3044658A1 (en) 2018-08-16
KR102539920B1 (ko) 2023-06-05
EP3581183A4 (en) 2020-12-09
RU2750539C2 (ru) 2021-06-29
JP6581320B2 (ja) 2019-09-25
RU2019120680A (ru) 2021-03-09
IL267159B (en) 2022-05-01
CN110072528B (zh) 2022-04-26
EP3581183B1 (en) 2023-11-29
CN110072528A (zh) 2019-07-30

Similar Documents

Publication Publication Date Title
BR122021024395A2 (ru)
BR122021023687A2 (ru)
BR122022003520A2 (ru)
RU2019120680A3 (ru)
BR122022025811B8 (ru)
BR112019008823A2 (ru)
BR202018014992U2 (ru)
BR202017025154U2 (ru)
BR102017023327A2 (ru)
BR202017021228U2 (ru)
BR202017020981U2 (ru)
BR202017017068U2 (ru)
BR202017016984U2 (ru)
BR202017016924U2 (ru)
BR102017015495A2 (ru)
BR202017012548U2 (ru)
BR202017011220U2 (ru)
BR202017010814U2 (ru)
BR202017010373U2 (ru)
BR202017009870U2 (ru)
BR202017006953U2 (ru)
BR202017004898U2 (ru)
BR202017002937U2 (ru)
BR202017002826U2 (ru)
CN303991468S (ru)